Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists

Fackrell, R., Carroll, C. B., Grosset, D. G. , Mohamed, B., Reddy, P., Parry, M., Chaudhuri, K. R. and Foltynie, T. (2018) Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. Neurodegenerative Disease Management, 8(5), pp. 349-360. (doi: 10.2217/nmt-2018-0020) (PMID:29975112)

Abstract

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Grosset, Professor Donald
• Authors: Fackrell, R., Carroll, C. B., Grosset, D. G., Mohamed, B., Reddy, P., Parry, M., Chaudhuri, K. R., and Foltynie, T.
• College/School: College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience
• Journal Name: Neurodegenerative Disease Management
• Publisher: Future Medicine
• ISSN: 1758-2024
• ISSN (Online): 1758-2032
• Published Online: 05 July 2018
• Copyright Holders: Copyright © 2018 Robin Fackrell
• First Published: First published in Neurodegenerative Disease Management 8(5):349-360
• Publisher Policy: Reproduced under a Creative Commons License